COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN IRANIAN ATRIAL FIBRILLATION PATIENTS
Author(s)
Keshavarz K1, Hashemi Meshkini A2, Nikfar S2, Ashkuh MS3, Sanati E4
1Shiraz University of Medical Sciences, School of Management and Information Sciences, Shiraz, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Shiraz University of Medical Sciences, Shiraz, Iran (Islamic Republic of), 4Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of)
OBJECTIVES: Atrial fibrillation (AF) is a common clinically cardiac rhythm abnormality associated with substantial morbidity and mortality. AF is the main cause of stroke and systematic embolism (SSE) which can lead to death, disability and quality of life impairment. The standard care for AF patients is vitamin K antagonists such as warfarin but some studies indicated that the rate of stroke and SSE will dabigatran were lower than those with warfarin. This study was aimed to estimate the cost-effectiveness dabigatran etexilate versus warfarin for prevention of stroke in Iranian patients with AF. METHODS: A Morkov micro-simulation model was constructed to analysis the cost-effectiveness of two treatment strategies (dose-adjusted warfarin and dabigatran 150mg twice daily) in AF patients. The designed model included eight disease states. Modelled outcome over a lifetime horizon was quality-adjusted life-years (QALYs) which was collected from previous published studies. Direct healthcare costs for each state and treatment strategy were determined from review of medical records, expert opinion and interview with patients. The results were presented in form of incremental cost-effectiveness ratio (ICER) and sensitivity analysis was carried out to indicate robustness of results. RESULTS: The QALYs values calculated for dabigatran and warfarin were 6.72 and 6.59 respectively. In addition, the costs for dabigatran and warfarin were obtained 10,251 and 8,270 $ respectively. Base on acceptability curve results in 45 to 60% range of simulations dabigatran was found to be a cost-effective strategy over warfarin (ICER=11,773 $/QALY) well below the local thresholds of acceptance; 51,909 $ PPP. The results were robust over a wide range of inputs in sensitivity analysis. CONCLUSIONS: This study suggests that the use of dabigatran for the prevention of stroke is likely to be cost-effective and also due to reduce drug monitoring and hospitalization time can represent as first priority treatment in Iranian AF patients.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCV100
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders